Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tsc1tm1Hin mutation
(0 available);
any
Tsc1 mutation
(69 available)
|
|
|
Analysis of Tsc1tm1Hin/Tsc1tm1Hin embryos
mortality/aging
|
|
• most embryos die between E10.5 and E11.5, although some survive to E12.5
|
growth/size/body
|
|
• embryos alive at E9-12.5 are smaller
|
embryo
|
|
• embryos alive at E9-12.5 are smaller
|
|
|
• 6 of 19 embryos exhibit neural tube unclosure at the head region; the neural tube is disorganized in these embryos
|
nervous system
|
|
• 6 of 19 embryos exhibit neural tube unclosure at the head region; the neural tube is disorganized in these embryos
|
cardiovascular system
|
|
• hearts of some embryos exhibit abnormal morphology of myocardial cells
|
liver/biliary system
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tsc1tm1Hin mutation
(0 available);
any
Tsc1 mutation
(69 available)
|
|
|
behavior/neurological
 |
• males spend less time in the dark chamber of the light/dark box, suggesting low anxiety
|
|
|
• in the tail flick test, males have a longer latencies than females
|
|
|
• increase in rearing behavior
• treatment with rapamycin attenuates rearing behavior
|
|
|
• mice spend a shorter time engaged in active interaction with a novel mouse than wild-type mice
• however, mice are not altered in social dominance, exhibit normal olfaction and exploration towards an inanimate object, and show intact motor and sensory function
• treatment with rapamycin extends the time of active interaction with a novel mouse
|
Allelic
Composition |
Tsc1tm1Hin/Tsc1+
|
|
Genetic
Background |
involves: 129S4/SvJae * C57BL/6J |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tsc1tm1Hin mutation
(0 available);
any
Tsc1 mutation
(69 available)
|
|
|
Renal tumors in Tsc1tm1Hin/Tsc1+ mice
mortality/aging
|
|
• notice sudden death of heterozygotes older than 18 months of age, probably as a result of the rupture of huge hepatic hemangiomas
|
neoplasm
|
|
• most tumors that develop exhibit loss of heterozygosity (LOH)
|
|
|
• tumors in extremities develop with a high frequency
|
|
|
• transplacental administration of ENU accelerates renal tumorigenesis compared to controls
|
 |
• detect leiomyoma/leiomyosarcoma in the uterus
|
|
|
• detect leiomyoma/leiomyosarcoma in the uterus
|
|
|
• mutants develop macroscopically visible renal carcinomas and/or renal cystadenomas by 10 months of age
|
|
|
• detect hemangioma in the tail
|
|
|
• about 80% of mutants develop hepatic hemangiomas by 15-18 months of age
|
|
|
• mutants develop macroscopically visible renal carcinomas and/or renal cystadenomas by 10 months of age
|
homeostasis/metabolism
renal/urinary system
|
|
• mutants develop macroscopically visible renal carcinomas and/or renal cystadenomas by 10 months of age
|
|
|
• mutants develop macroscopically visible renal carcinomas and/or renal cystadenomas by 10 months of age
|
muscle
|
|
• detect leiomyoma/leiomyosarcoma in the uterus
|
|
|
• detect leiomyoma/leiomyosarcoma in the uterus
|
liver/biliary system
|
|
• about 80% of mutants develop hepatic hemangiomas by 15-18 months of age
|
reproductive system
|
|
• detect leiomyoma/leiomyosarcoma in the uterus
|
Analysis Tools